Leininger, Simon B. and Staudner, Stephan T. and Vogel, Manuel J. and Mustroph, Julian and Hubauer, Ute and Wallner, Stefan and Lehn, Petra and Burkhardt, Ralph and Meindl, Christine and Hanses, Frank and Zimmermann, Markus and Maier, Lars S. and Hupf, Julian and Jungbauer, Carsten G. (2024) Bioactive adrenomedullin and interleukin-6 in COVID-19: potential biomarkers of acute kidney injury and critical illness. BMC NEPHROLOGY, 25 (1): 52. ISSN , 1471-2369
Full text not available from this repository. (Request a copy)Abstract
Background The aim of this study was to investigate whether bioactive adrenomedullin (bio-ADM) and interleukin-6 (IL-6) are related to acute kidney injury (AKI) and severe illness in COVID-19 patients. Methods 153 patients with COVID-19 admitted to the emergency department (ED) were included. Blood samples were collected from each patient at admission. Bio-ADM and IL-6, as well as DPP3 and routinely measured markers were evaluated regarding the endpoints AKI (22/128 hospitalized patients) and a composite endpoint of admission to intensive care unit and/or in-hospital death (n = 26/153 patients). Results Bio-ADM and IL-6 were significantly elevated in COVID-19 patients with AKI compared to COVID-19 patients without AKI (each p < 0.001). According to ROC analyses IL-6 and bio-ADM had the largest AUC (0.84 and 0.81) regarding the detection of AKI. Furthermore, bio-ADM and IL-6 were significantly elevated in COVID-19 patients reaching the composite endpoint (each p < 0.001). Regarding the composite endpoint ROC analysis showed an AUC of 0.89 for IL-6 and 0.83 for bio-ADM in COVID-19 patients. In the multivariable logistic model bio-ADM and IL-6 presented as independent significant predictors regarding both endpoints AKI and the composite endpoint in COVID-19 patients (as well as creatinine regarding the composite endpoint; each p < 0.05), opposite to leukocytes, C-reactive protein (CRP) and dipeptidyl peptidase 3 (DPP3; each p = n.s.). Conclusion Elevated levels of bio-ADM and IL-6 are associated with AKI and critical illness in patients with COVID-19. Therefore, both biomarkers may be potential tools in risk stratification in COVID-19 patients at presentation in the ED.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | MORTALITY; COVID-19; SARS-CoV-2; Adrenomedullin; Interleukin-6; Acute Kidney Injury |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Innere Medizin II Medicine > Lehrstuhl für Klinische Chemie und Laboratoriumsmedizin Medicine > Abteilung für Krankenhaushygiene und Infektiologie |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 25 Jul 2025 11:07 |
| Last Modified: | 25 Jul 2025 11:07 |
| URI: | https://pred.uni-regensburg.de/id/eprint/63799 |
Actions (login required)
 |
View Item |
